<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03063437</url>
  </required_header>
  <id_info>
    <org_study_id>200-2016-91948</org_study_id>
    <nct_id>NCT03063437</nct_id>
  </id_info>
  <brief_title>A Trial of Encapsulated Fecal Microbiota for Vancomycin Resistant Enterococcus Decolonization</brief_title>
  <official_title>Phase II Randomized, Double Blind, Placebo-controlled, Parallel Group Trial of Encapsulated Fecal Microbiota Transplantation for Vancomycin Resistant Enterococcus Decolonization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Microbiome Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Microbiome Health Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to provide preliminary insight into the safety and efficacy of
      fecal microbiota transplantation (FMT) for the eradication of gastrointestinal carriage of
      vancomycin-resistant Enterococcus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Note: The Protocol and Statistical Analysis Plan document contains modifications from what is
      on file at the FDA to reflect redactions and formatting requirements for public posting on
      ClinicalTrials.gov.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 17, 2017</start_date>
  <completion_date type="Actual">February 26, 2019</completion_date>
  <primary_completion_date type="Actual">September 19, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With VRE Decolonization</measure>
    <time_frame>Day 10 (±3 days) after randomization</time_frame>
    <description>VRE decolonization is defined by absence of VRE on stool culture using standard clinical laboratory techniques at Day 10 (± 3 days) after randomization.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With an Adverse Event (AE); Severe Adverse Event (SAE); and Newly Acquired Transmissible Infectious Diseases Which Are Considered Adverse Events of Special Interest (AESI)</measure>
    <time_frame>Day 10 (±3 days) after randomization</time_frame>
    <description>Percentage of participants with an adverse event (AE); severe adverse event (SAE); and newly acquired transmissible infectious diseases which are considered adverse events of special interest (AESI) through Day 10 (± 3 days) after randomization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With VRE Infection</measure>
    <time_frame>Week 4 (±5 days) after randomization</time_frame>
    <description>Percentage of participants with VRE infection, defined as an associated bacteremia, urinary tract infection, or wound-related infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With ARB Colonization on Day 10 Following Fecal Microbiota Transplantation (FMT)</measure>
    <time_frame>Day 10 (± 3 days) after randomization</time_frame>
    <description>Percentage of participants with other antibiotic resistant bacteria (ARB) colonization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With ARB Infection 4 Weeks Following FMT</measure>
    <time_frame>Week 4 (±5 days) after randomization</time_frame>
    <description>Percentage of participants with composite ARB infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days Between FMT and VRE Colonization and Infection Occurs</measure>
    <time_frame>Up to 6 months after randomization</time_frame>
    <description>Time (in days) from randomization until the study day when VRE colonization and infection occurs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VRE Decolonization Among Immunocompromised Patients</measure>
    <time_frame>Day 10 (± 3 days) after randomization</time_frame>
    <description>Percentage of participants with VRE decolonization among immunocompromised patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events Within 4 Weeks Following FMT</measure>
    <time_frame>Week 4 (±5 days) after randomization</time_frame>
    <description>Percentage of participants with an adverse event (AE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events Within 4 Weeks Following FMT</measure>
    <time_frame>Week 4 (±5 days) after randomization</time_frame>
    <description>Percentage of participants with a serious adverse event (SAE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Newly Acquired Transmissible Infectious Diseases Which Are Considered Adverse Events of Special Interest (AESI)</measure>
    <time_frame>Week 4 (±5 days) after randomization</time_frame>
    <description>Percentage of participants with newly acquired transmissible infectious diseases which are considered adverse events of special interest (AESI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events Within 6 Months Following FMT</measure>
    <time_frame>Month 6 (±14 days) phone safety assessment after randomization</time_frame>
    <description>Percentage of participants with a Serious Adverse Event (SAE)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Microbiome Disruption</measure>
    <time_frame>Day 3, day 10, week 4 after randomization.</time_frame>
    <description>To evaluate the microbiome disruption index (MDI) by 16s rRNA sequencing): MDI-community and MDI-species</description>
  </other_outcome>
  <other_outcome>
    <measure>Engraftment Dynamics</measure>
    <time_frame>6 months following FMT</time_frame>
    <description>To evaluate the trends in VRE type/strain-level engraftment using whole genome sequencing among those colonized</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Antibiotic Resistant Strain</condition>
  <arm_group>
    <arm_group_label>Active: Encapsulated Fecal Microbiota Preparation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of oral, encapsulated fecal microbiota preparation (30 capsules per dose) with follow-up at 3 days, 10 days, 28 days, and 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo: Encapsulated Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of oral, placebo capsule (30 capsules per dose) with follow-up at 3 days, 10 days, and 28 days, and 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Encapsulated fecal microbiota preparation</intervention_name>
    <description>30 capsules</description>
    <arm_group_label>Active: Encapsulated Fecal Microbiota Preparation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Encapsulated placebo</intervention_name>
    <description>30 capsules</description>
    <arm_group_label>Placebo: Encapsulated Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults 18 years or older at the time of enrollment.

          -  Able to provide signed and dated informed consent.

          -  Identified as VRE-positive by a stool culture within last 14 days.

          -  Women of childbearing potential in sexual relationships with men must use an
             acceptable method of contraception§ from 30 days prior to enrollment until 4 weeks
             after completing study treatment.

          -  Males must agree to avoid impregnation of women during and for four weeks after
             completing study treatment through use of an acceptable method of contraception*.

               -  Includes, but is not limited to, barrier with additional spermicidal foam or
                  jelly, intrauterine device, hormonal contraception (started at least 30 days
                  prior to study enrollment), intercourse with men who underwent vasectomy.

                    -  Includes, but is not limited to, barrier with additional spermicidal foam or
                       jelly and vasectomy.

        Exclusion Criteria:

          -  Female patient who are pregnant, lactating or planning on becoming pregnant during
             study. Female patients of childbearing potential will undergo a pregnancy test, and be
             excluded from the study if positive.

          -  Inability (e.g. dysphagia) to or unwilling to swallow capsules.

          -  Active antibiotic resistant bacteria (ARB) or gastrointestinal infection at time of
             enrollment.

          -  Patient received antibiotics in the last 48 hours. Patients will be eligible to enroll
             if antibiotic therapy is discontinued for at minimum 48 hours prior to randomization.
             Does not include antibiotics used for prophylaxis or topical antibiotics.

          -  Requires continued antibiotic use or anticipates antibiotic use in the upcoming 4
             weeks. Does not include antibiotics used for prophylaxis or topical antibiotics.

          -  Unwilling to withhold probiotics for a minimum of 48 hours prior to providing a
             screening stool sample.

          -  Known or suspected toxic megacolon and/or known small bowel ileus.

          -  Major gastrointestinal surgery (e.g. significant bowel resection) within 3 months
             before enrollment. This does not include appendectomy or cholecystectomy.

          -  History of total colectomy or bariatric surgery.

          -  Admitted to or expected to an intensive care unit for medical reasons (not just
             boarding). Patients residing in a nursing home, long-term care facility or
             rehabilitation center may be enrolled.

          -  Concurrent intensive induction chemotherapy, radiation therapy or biological treatment
             for active malignancy. Patients on maintenance chemotherapy may be enrolled only after
             consultation with medical monitor.

          -  Unable or unwilling to comply with protocol requirements.

          -  Expected life expectancy &lt; 6 months

          -  Previous FMT or microbiome-based products at any time excluding this study.

          -  Patients with a history of severe anaphylactic or anaphylactoid food allergy.

          -  Solid organ transplant recipients ≤ 90 days post-transplant or on active treatment for
             rejection.

          -  Neutropenia (≤500 neutrophils/mL) or other severe immunosuppression. Anti-TNF will be
             permitted. Patients on monoclonal antibodies to B and T cells. glucocorticoids,
             antimetabolites (azathioprine, 6-mercaptopurine, methotrexate), calcineurin inhibitors
             (tacrolimus, cyclosporine) and mycophenolate mofetil may be enrolled only after
             consultation with the medical monitor.

          -  If at risk for CMV/EBV associated disease (at investigator's discretion, e.g.
             immunocompromised), negative IgG testing for cytomegalovirus (CMV) or Epstein Barr
             Virus (EBV).

          -  A condition that would jeopardize the safety or rights of the subject, would make it
             unlikely for the subject to complete the study, or would confound the results of the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Majdi Osman, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Microbiome Health Research Institute d/b/a OpenBiome</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IU Health University Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin University Hospital</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 17, 2017</study_first_submitted>
  <study_first_submitted_qc>February 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2017</study_first_posted>
  <results_first_submitted>January 15, 2020</results_first_submitted>
  <results_first_submitted_qc>January 15, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 5, 2020</results_first_posted>
  <last_update_submitted>April 1, 2020</last_update_submitted>
  <last_update_submitted_qc>April 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vancomycin resistant enterococcus</keyword>
  <keyword>VRE</keyword>
  <keyword>decolonization</keyword>
  <keyword>VRE colonization</keyword>
  <keyword>fecal microbiota transplantation</keyword>
  <keyword>FMT</keyword>
  <keyword>FMT capsule</keyword>
  <keyword>capsule</keyword>
  <keyword>antimicrobial resistance</keyword>
  <keyword>antibiotic resistance</keyword>
  <keyword>MDRO</keyword>
  <keyword>multidrug-resistant organism</keyword>
  <keyword>OpenBiome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sprains and Strains</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 9, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/37/NCT03063437/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited at the listed tertiary academic hospitals from August 15, 2017 to September 30, 2018.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Active: Encapsulated Fecal Microbiota Preparation</title>
          <description>Single dose of oral, encapsulated fecal microbiota preparation (30 capsules per dose) with follow-up at 3 days, 10 days, 28 days, and 6 months.</description>
        </group>
        <group group_id="P2">
          <title>Placebo: Encapsulated Placebo</title>
          <description>Single dose of oral, placebo capsule (30 capsules per dose) with follow-up at 3 days, 10 days, 28 days, and 6 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active: Encapsulated Fecal Microbiota Preparation</title>
          <description>Single dose of oral, encapsulated fecal microbiota preparation (30 capsules per dose) with follow-up at 3 days, 10 days, 28 days, and 6 months.</description>
        </group>
        <group group_id="B2">
          <title>Placebo: Encapsulated Placebo</title>
          <description>Single dose of oral, placebo capsule (30 capsules per dose) with follow-up at 3 days, 10 days, 28 days, and 6 months.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With VRE Decolonization</title>
        <description>VRE decolonization is defined by absence of VRE on stool culture using standard clinical laboratory techniques at Day 10 (± 3 days) after randomization.</description>
        <time_frame>Day 10 (±3 days) after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active: Encapsulated Fecal Microbiota Preparation</title>
            <description>Single dose of oral, encapsulated fecal microbiota preparation (30 capsules per dose) with follow-up at 3 days, 10 days, 28 days, and 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Encapsulated Placebo</title>
            <description>Single dose of oral, placebo capsule (30 capsules per dose) with follow-up at 3 days, 10 days, 28 days, and 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With VRE Decolonization</title>
          <description>VRE decolonization is defined by absence of VRE on stool culture using standard clinical laboratory techniques at Day 10 (± 3 days) after randomization.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With an Adverse Event (AE); Severe Adverse Event (SAE); and Newly Acquired Transmissible Infectious Diseases Which Are Considered Adverse Events of Special Interest (AESI)</title>
        <description>Percentage of participants with an adverse event (AE); severe adverse event (SAE); and newly acquired transmissible infectious diseases which are considered adverse events of special interest (AESI) through Day 10 (± 3 days) after randomization.</description>
        <time_frame>Day 10 (±3 days) after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active: Encapsulated Fecal Microbiota Preparation</title>
            <description>Single dose of oral, encapsulated fecal microbiota preparation (30 capsules per dose) with follow-up at 3 days, 10 days, 28 days, and 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Encapsulated Placebo</title>
            <description>Single dose of oral, placebo capsule (30 capsules per dose) with follow-up at 3 days, 10 days, 28 days, and 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an Adverse Event (AE); Severe Adverse Event (SAE); and Newly Acquired Transmissible Infectious Diseases Which Are Considered Adverse Events of Special Interest (AESI)</title>
          <description>Percentage of participants with an adverse event (AE); severe adverse event (SAE); and newly acquired transmissible infectious diseases which are considered adverse events of special interest (AESI) through Day 10 (± 3 days) after randomization.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With VRE Infection</title>
        <description>Percentage of participants with VRE infection, defined as an associated bacteremia, urinary tract infection, or wound-related infection.</description>
        <time_frame>Week 4 (±5 days) after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active: Encapsulated Fecal Microbiota Preparation</title>
            <description>Single dose of oral, encapsulated fecal microbiota preparation (30 capsules per dose) with follow-up at 3 days, 10 days, 28 days, and 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Encapsulated Placebo</title>
            <description>Single dose of oral, placebo capsule (30 capsules per dose) with follow-up at 3 days, 10 days, 28 days, and 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With VRE Infection</title>
          <description>Percentage of participants with VRE infection, defined as an associated bacteremia, urinary tract infection, or wound-related infection.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With ARB Colonization on Day 10 Following Fecal Microbiota Transplantation (FMT)</title>
        <description>Percentage of participants with other antibiotic resistant bacteria (ARB) colonization</description>
        <time_frame>Day 10 (± 3 days) after randomization</time_frame>
        <population>Data not collected as no participants in the trial entered the study colonized with an ARB other than VRE</population>
        <group_list>
          <group group_id="O1">
            <title>Active: Encapsulated Fecal Microbiota Preparation</title>
            <description>Single dose of oral, encapsulated fecal microbiota preparation (30 capsules per dose) with follow-up at 3 days, 10 days, 28 days, and 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Encapsulated Placebo</title>
            <description>Single dose of oral, placebo capsule (30 capsules per dose) with follow-up at 3 days, 10 days, 28 days, and 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With ARB Colonization on Day 10 Following Fecal Microbiota Transplantation (FMT)</title>
          <description>Percentage of participants with other antibiotic resistant bacteria (ARB) colonization</description>
          <population>Data not collected as no participants in the trial entered the study colonized with an ARB other than VRE</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With ARB Infection 4 Weeks Following FMT</title>
        <description>Percentage of participants with composite ARB infection</description>
        <time_frame>Week 4 (±5 days) after randomization</time_frame>
        <population>Data not collected as no participants in the trial entered the study colonized with an ARB other than VRE</population>
        <group_list>
          <group group_id="O1">
            <title>Active: Encapsulated Fecal Microbiota Preparation</title>
            <description>Single dose of oral, encapsulated fecal microbiota preparation (30 capsules per dose) with follow-up at 3 days, 10 days, 28 days, and 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Encapsulated Placebo</title>
            <description>Single dose of oral, placebo capsule (30 capsules per dose) with follow-up at 3 days, 10 days, 28 days, and 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With ARB Infection 4 Weeks Following FMT</title>
          <description>Percentage of participants with composite ARB infection</description>
          <population>Data not collected as no participants in the trial entered the study colonized with an ARB other than VRE</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days Between FMT and VRE Colonization and Infection Occurs</title>
        <description>Time (in days) from randomization until the study day when VRE colonization and infection occurs</description>
        <time_frame>Up to 6 months after randomization</time_frame>
        <population>Data not collected as no participants in the trial were colonized and infected by VRE following randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Active: Encapsulated Fecal Microbiota Preparation</title>
            <description>Single dose of oral, encapsulated fecal microbiota preparation (30 capsules per dose) with follow-up at 3 days, 10 days, 28 days, and 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Encapsulated Placebo</title>
            <description>Single dose of oral, placebo capsule (30 capsules per dose) with follow-up at 3 days, 10 days, 28 days, and 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days Between FMT and VRE Colonization and Infection Occurs</title>
          <description>Time (in days) from randomization until the study day when VRE colonization and infection occurs</description>
          <population>Data not collected as no participants in the trial were colonized and infected by VRE following randomization.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VRE Decolonization Among Immunocompromised Patients</title>
        <description>Percentage of participants with VRE decolonization among immunocompromised patients</description>
        <time_frame>Day 10 (± 3 days) after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active: Encapsulated Fecal Microbiota Preparation</title>
            <description>Single dose of oral, encapsulated fecal microbiota preparation (30 capsules per dose) with follow-up at 3 days, 10 days, 28 days, and 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Encapsulated Placebo</title>
            <description>Single dose of oral, placebo capsule (30 capsules per dose) with follow-up at 3 days, 10 days, 28 days, and 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>VRE Decolonization Among Immunocompromised Patients</title>
          <description>Percentage of participants with VRE decolonization among immunocompromised patients</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events Within 4 Weeks Following FMT</title>
        <description>Percentage of participants with an adverse event (AE)</description>
        <time_frame>Week 4 (±5 days) after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active: Encapsulated Fecal Microbiota Preparation</title>
            <description>Single dose of oral, encapsulated fecal microbiota preparation (30 capsules per dose) with follow-up at 3 days, 10 days, 28 days, and 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Encapsulated Placebo</title>
            <description>Single dose of oral, placebo capsule (30 capsules per dose) with follow-up at 3 days, 10 days, 28 days, and 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events Within 4 Weeks Following FMT</title>
          <description>Percentage of participants with an adverse event (AE)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serious Adverse Events Within 4 Weeks Following FMT</title>
        <description>Percentage of participants with a serious adverse event (SAE)</description>
        <time_frame>Week 4 (±5 days) after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active: Encapsulated Fecal Microbiota Preparation</title>
            <description>Single dose of oral, encapsulated fecal microbiota preparation (30 capsules per dose) with follow-up at 3 days, 10 days, 28 days, and 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Encapsulated Placebo</title>
            <description>Single dose of oral, placebo capsule (30 capsules per dose) with follow-up at 3 days, 10 days, 28 days, and 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Adverse Events Within 4 Weeks Following FMT</title>
          <description>Percentage of participants with a serious adverse event (SAE)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Newly Acquired Transmissible Infectious Diseases Which Are Considered Adverse Events of Special Interest (AESI)</title>
        <description>Percentage of participants with newly acquired transmissible infectious diseases which are considered adverse events of special interest (AESI)</description>
        <time_frame>Week 4 (±5 days) after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active: Encapsulated Fecal Microbiota Preparation</title>
            <description>Single dose of oral, encapsulated fecal microbiota preparation (30 capsules per dose) with follow-up at 3 days, 10 days, 28 days, and 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Encapsulated Placebo</title>
            <description>Single dose of oral, placebo capsule (30 capsules per dose) with follow-up at 3 days, 10 days, 28 days, and 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Newly Acquired Transmissible Infectious Diseases Which Are Considered Adverse Events of Special Interest (AESI)</title>
          <description>Percentage of participants with newly acquired transmissible infectious diseases which are considered adverse events of special interest (AESI)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serious Adverse Events Within 6 Months Following FMT</title>
        <description>Percentage of participants with a Serious Adverse Event (SAE)</description>
        <time_frame>Month 6 (±14 days) phone safety assessment after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active: Encapsulated Fecal Microbiota Preparation</title>
            <description>Single dose of oral, encapsulated fecal microbiota preparation (30 capsules per dose) with follow-up at 3 days, 10 days, 28 days, and 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Encapsulated Placebo</title>
            <description>Single dose of oral, placebo capsule (30 capsules per dose) with follow-up at 3 days, 10 days, 28 days, and 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Adverse Events Within 6 Months Following FMT</title>
          <description>Percentage of participants with a Serious Adverse Event (SAE)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Microbiome Disruption</title>
        <description>To evaluate the microbiome disruption index (MDI) by 16s rRNA sequencing): MDI-community and MDI-species</description>
        <time_frame>Day 3, day 10, week 4 after randomization.</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Engraftment Dynamics</title>
        <description>To evaluate the trends in VRE type/strain-level engraftment using whole genome sequencing among those colonized</description>
        <time_frame>6 months following FMT</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected for 6 months after randomization,</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Active: Encapsulated Fecal Microbiota Preparation</title>
          <description>Encapsulated fecal microbiota preparation: 30 capsules</description>
        </group>
        <group group_id="E2">
          <title>Placebo: Encapsulated Placebo</title>
          <description>Encapsulated placebo: 30 capsules</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Congestive Heart Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Eye</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Abdominal distention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Discolored stool</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Throat pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <description>General disorders and administration site conditions</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Loss of appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated liver function tests</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Polymyalgia rheumatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>CMV re-activation</sub_title>
                <description>Cytomegalovirus (CMV) re-activation</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Majdi Osman, MD, MPH</name_or_title>
      <organization>Microbiome Health Research Institute</organization>
      <phone>6175752201</phone>
      <email>majdi@openbiome.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

